IntelGenx Corp. Pitch Deck Teardown: Scaling Drug Delivery

IntelGenx Corp. Investor Presentation: A Deep Dive into Drug Delivery Innovation

The January 2016 investor presentation for IntelGenx Corp. (TSX-V: IGX, OTCQX: IGXT) provides a comprehensive look at a pharmaceutical company positioned at the intersection of proven chemistry and innovative delivery. The central thesis of the deck is simple yet powerful: 'We Make Approved Drugs Better.' By focusing on oral thin films and advanced tablet formulations, IntelGenx seeks to capture a share of a multi-billion dollar market with lower clinical risk than traditional biotech firms.

Slide 1: Title and Positioning

The cover slide establishes the company's identity as a provider of 'Innovative Drug Delivery Solutions.' It clearly lists its public trading symbols for both the TSX Venture Exchange and the OTCQX, signaling transparency and liquidity to potential investors. The tagline 'We Make Approved Drugs Better' immediately informs the reader of their business model: enhancing existing therapeutics rather than inventing new ones.

Slide 2: The Oral Thin Film Opportunity

Slide 2 uses a recognizable consumer product—Listerine Cool Mint Pocketpaks—to anchor the concept of oral thin films (OTF). This is a brilliant use of analogy. By stating that the IGX CEO was a co-developer of the Listerine breath strips, the company establishes immediate technical credibility. The slide lists three key benefits of OTFs: suitability for patients who struggle with swallowing (elderly and children), and quicker action for symptom relief. This slide successfully bridges the gap between a familiar consumer technology and a sophisticated medical application.

Slide 4: Investment Highlights

This slide serves as the executive summary. It quantifies the opportunity, citing a $19B Total Addressable Market (TAM). Key achievements are listed to show momentum: market success with Forfivo XL tablets, European approval for RIZAPORT for migraines, and record Q3 revenue and profitability. The slide also introduces the two primary brands: VersaFilm ($17B TAM) and VersaTab ($1.7B TAM). The visual layout is clean, using icons to represent the film and tablet formats.

Slide 6: VersaFilm Platform Deep Dive

Slide 6 breaks down the $17B VersaFilm opportunity into specific therapeutic categories. It highlights the clinical benefits: improved compliance, rapid disintegration without water, and faster onset of action. The market breakdown is specific: Opioid Dependence ($1.7B), Migraine ($2B), Schizophrenia ($5.2B), and Erectile Dysfunction ($4.2B). By naming specific target drugs like Suboxone and Cialis, the company makes the commercial path tangible for investors.

Slide 8: The Product Pipeline

A standard but essential component of any pharma deck, the pipeline slide shows the breadth of IntelGenx's work. It lists 14 different indications. The chart tracks progress from formulation development through to launch. Notably, it includes 'Partnering Availability,' showing which programs are already tied to partners like Par Pharmaceuticals or Edgemont Pharmaceuticals, and which are still available for licensing. This transparency helps investors understand the future revenue potential from milestones and royalties.

Slide 10: In-House Manufacturing Strategy

This slide marks a strategic shift from a pure R&D shop to an integrated manufacturer. IntelGenx outlines its 'Full Manufacturing Capabilities,' including blending, coating, and packaging. The stated goals are to increase profitability, protect IP, and offer 'one-stop shopping' for clients. For a micro-cap pharma company, owning the manufacturing process is a significant moat that can prevent the delays and margin compression often associated with contract manufacturing organizations (CMOs).

Slide 12: Financial Performance

The financial slide is a highlight of the deck, showing a dramatic revenue spike. Q3 2015 revenue of $2.38M is contrasted against Q3 2014's $0.45M. The nine-month comparison is even more stark: $3.59M in 2015 versus $0.83M in 2014. This visual evidence of 'strong execution of strategy' provides the quantitative proof needed to back up the qualitative claims made in earlier slides.

Slide 14: Leadership and Expertise

The team slide emphasizes '100+ years of combined industry experience.' It features six key executives, highlighting their backgrounds at companies like LTS, Neptune, and Paladin. The technical depth is reinforced by the closing note: 'Currently 18 Employees, 8 Ph.D.’s.' This high ratio of advanced degrees to total headcount suggests a lean, highly specialized organization focused on technical excellence.

Slide 16: Conclusion

The deck concludes with a simple 'Thank You' and the company website. While it lacks a specific 'Ask' slide in this 9-slide subset, the preceding slides have built a case for a company that is growing revenue, expanding its technical capabilities, and targeting massive markets with a proven leadership team.

What IntelGenx Does Well

IntelGenx excels at simplifying a complex technical value proposition. By using the Listerine analogy, they remove the 'fear of the unknown' regarding their primary delivery method. They also do an excellent job of quantifying their markets. Instead of just saying 'the market is big,' they break it down by specific indication and even specific competitor drugs. The inclusion of a detailed pipeline and clear financial growth charts provides a balanced view of both the future potential and the current operational success.

What is Missing from the Deck

While the deck is strong on strategy and technology, there are a few notable omissions in this set of slides. First, there is no explicit 'Ask' or 'Use of Funds' slide, which is critical for an investor presentation. Second, while they mention 'limited number of competitors' on Slide 6, they do not provide a competitive matrix or a direct comparison to other drug delivery companies. Finally, the deck lacks a detailed breakdown of their IP portfolio; while they mention '40 patents' for the CEO, a slide dedicated to the company's specific patent protections for VersaFilm and VersaTab would strengthen the 'moat' argument.

Founder Takeaways: What to Copy

Use Familiar Analogies: If your technology is novel, compare it to a well-known consumer product (like the Listerine strips) to help investors 'get it' instantly. · Quantify the TAM by Segment: Don't just give one giant number. Break your market down into logical sub-sectors to show you understand the specific niches you are entering. · Show, Don't Just Tell, Growth: The bar chart on Slide 12 is effective because it uses color-coded boxes to highlight the most important growth metrics, making the data easy to digest at a glance. · Highlight Technical Density: If you have a small team with a high number of advanced degrees, call it out. It signals that your overhead is going toward high-value intellectual capital. · Vertical Integration as a Value Add: If you are moving from a service or R&D model to a manufacturing model, clearly explain the benefits to the customer (e.g., 'one-stop shopping') and the benefit to the company (e.g., 'IP protection').